Rauf Haznedar

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

Meral Beksaç, Rauf Haznedar, Tülin Firatli‐Tuglular et al. · European Journal Of Haematology · 2010 · 143 citations

Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma

Rauf Haznedar, Şahika Zeynep Akı, Ümit Özgür Akdemir et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2011 · 86 citations

Positron Emission Tomography, Hematological Malignancy, 18F-fluorodeoxyglucose Uptake +10

Tumor-associated macrophages as a prognostic parameter in multiple myeloma

Elif Suyanı, Gülsan Türköz Sucak, Nalân Akyürek et al. · Annals of Hematology · 2013 · 85 citations

Hematological Malignancy, Medicine, Immunology +4

Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony‐stimulating factor (rhG‐CSF): a randomized evaluation of different doses of rhG‐CSF

Taner Demirer, Muhıt Özcan, Nazan Günel et al. · British Journal of Haematology · 2002 · 70 citations · Full text

Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid

Sedat Çeti̇ner, Gülsan Türköz Sucak, Sevil Kahraman et al. · Journal of Bone and Mineral Metabolism · 2009 · 55 citations

Bone Disease, Zoledronic Acid, Bone Health +6